AXL and cancer: NCI-H820 cancer cells express an EGFR drug-sensitive mutation (an exon 19 deletion), an EGFR drug-resistance mutation (T790M), activated AXL, and MET amplification, conferring resistance to erlotinib, gefitinib, and afatinib [19,49].